V. Phan

发表

Ethnic differences in drug metabolism and toxicity from chemotherapy

S. Clarke, A. McLachlan, Hongmei Xu, 2009 .

Ethnicdifferencesindrug metabolismandtoxicity fromchemotherapy

S. Clarke, A. McLachlan, Hongmei Xu, 2009 .

Ethnic differences in drug metabolism and toxicity from chemotherapy.

S. Clarke, A. McLachlan, Hongmei Xu, 2009, Expert opinion on drug metabolism & toxicology.

Predictive markers for haematological toxicity of pemetrexed.

S. Clarke, S. Kao, V. Phan, 2010, Current drug targets.

Use of Inflammatory Markers to Guide Cancer Treatment

D. McMillan, S. Kao, W. Chua, 2011, Clinical pharmacology and therapeutics.

Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes

Jennifer H. Martin, S. Clarke, A. McLachlan, 2020, Clinical Pharmacokinetics.

An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs

S. Clarke, A. McLachlan, Hongmei Xu, 2011, Expert opinion on drug metabolism & toxicology.

The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study

P. Beale, S. Clarke, J. Peat, 2015, Supportive Care in Cancer.

Eastern Cooperative Oncology Group score: Agreement between non-small-cell lung cancer patients and their oncologists and clinical implications

S. Clarke, S. Kao, J. Vardy, 2016 .